Kindai University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2021

  1. The patient's perspective on treatment with dacomitinib: Patient-reported outcomes from the Phase III trial ARCHER 1050

    Future Oncology, Vol. 17, Núm. 7, pp. 783-794

  2. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

    Drugs, Vol. 81, Núm. 2, pp. 257-266

2019

  1. Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer

    Future Oncology, Vol. 15, Núm. 24, pp. 2795-2805

  2. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: A pooled safety analysis

    Future Oncology, Vol. 15, Núm. 13, pp. 1481-1491

2018

  1. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations

    Journal of Clinical Oncology, Vol. 36, Núm. 22, pp. 2244-2250

2017

  1. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 11, pp. 1454-1466